Neogenomics: sees FY2026 adj EBITDA $56 mln to $58 mln

NeoGenomics Inc. (NYSE: NEOG) has provided an updated outlook for fiscal year 2026, projecting adjusted EBITDA in the range of $56 million to $58 million. This guidance reflects the company’s performance and strategic direction as outlined in first-quarter 2026 results. The forecast indicates a continued focus on operational efficiency and growth within the oncology diagnostics sector. The company’s updated financial expectations are based on current market conditions and internal performance metrics. Investors are advised to consider these figures in the context of broader industry trends and the company’s long-term strategic goals. The guidance underscores NeoGenomics’ commitment to disciplined financial management and innovation in diagnostic services.